Treatment | Resource use (days) | Source | |
---|---|---|---|
Treatment duration | |||
First-line treatment for IA | Isavuconazole | 47.1 (IV: 8.1) | |
Voriconazole | 47.1 (IV: 8.1) | ||
First-line treatment for mucormycosis | Isavuconazole Voriconazole no pathogen information available Voriconazole non-responders prior to switching | 149.0 (IV: 15.5) 47.1 (IV: 8.1) 11.0 (IV: 8.1) | Mean treatment duration from VITAL [12, 36] Patients treated as IA patients, assumption follows SECURE [11, 39] Median time between first clinical signs and mucormycosis diagnosis, Xhaard et al. [17] |
Second-line treatment for IA | L-AmB | 14.5 (IV: 14.5) | Median treatment duration from Leenders et al. [19] |
Oral step-down with voriconazole or posaconazole | 32.6 (IV: 0) | Total duration of second-line treatment b minus duration of treatment with liposomal amphotericin-B | |
Second-line treatment for mucormycosis | L-AmB | 27.2 (IV: 27.2) | Median treatment duration from VITAL Fungiscope case-control [12, 36] |
Posaconazole | 121.8 (IV: 0) | Total duration of second-line treatmentc minus duration of treatment with liposomal amphotericin-B | |
Length of hospital stay | |||
IA | Isavuconazole Voriconazole L-AmB | 19.7 19.7 19.7 | |
Mucormycosis | Isavuconazole | 19.3 | |
Voriconazole no pathogen information available | 19.3 | Assumption same as for isavuconazole | |
Voriconazole non-responders prior to switching | 11.0 | Duration of treatment before mucormycosis diagnosis from Xhaard et al. [17] | |
L-AmB + posaconazole | 27.2 | Assumed: Duration the same as the mean days of IV treatment in Fungiscope case-control (VITAL [12, 36]) |